Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline Review, H1 2017’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects

The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aevi Genomic Medicine Inc

Alcobra Ltd

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arbor Pharmaceuticals LLC

BCWorld Pharm Co Ltd

BioHealthonomics Inc

BioLite Inc

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DURECT Corp

Eli Lilly and Company

Ensysce Biosciences Inc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Highland Therapeutics Inc

Integrative Research Laboratories Sweden AB

INVENT Pharmaceuticals Inc

KemPharm Inc

Luc Therapeutics Inc

Merck & Co Inc

Neos Therapeutics Inc

NeuroDerm Ltd

Neurovance Inc

NLS Pharma Group

Noven Pharmaceuticals Inc

P2D Bioscience

Reviva Pharmaceuticals Inc

Shire Plc

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Taisho Pharmaceutical Co Ltd

TRImaran Pharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Attention Deficit Hyperactivity Disorder (ADHD) - Overview 8

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development 29

Aevi Genomic Medicine Inc 29

Alcobra Ltd 29

Amarantus Bioscience Holdings Inc 30

APeT Holding BV 30

Arbor Pharmaceuticals LLC 31

BCWorld Pharm Co Ltd 31

BioHealthonomics Inc 32

BioLite Inc 32

Cingulate Therapeutics LLC 33

Collegium Pharmaceutical Inc 33

Curemark LLC 34

DURECT Corp 34

Eli Lilly and Company 35

Ensysce Biosciences Inc 35

H. Lundbeck A/S 36

Heptares Therapeutics Ltd 36

Highland Therapeutics Inc 37

Integrative Research Laboratories Sweden AB 37

INVENT Pharmaceuticals Inc 38

KemPharm Inc 38

Luc Therapeutics Inc 39

Merck & Co Inc 39

Neos Therapeutics Inc 40

NeuroDerm Ltd 40

Neurovance Inc 41

NLS Pharma Group 41

Noven Pharmaceuticals Inc 42

P2D Bioscience 42

Reviva Pharmaceuticals Inc 43

Shire Plc 43

SK Biopharmaceuticals Co Ltd 44

Sunovion Pharmaceuticals Inc 44

Supernus Pharmaceuticals Inc 45

Taisho Pharmaceutical Co Ltd 45

TRImaran Pharma Inc 46

Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles 47

(nicotine + opipramol hydrochloride) - Drug Profile 47

4-P003 - Drug Profile 48

AR-08 - Drug Profile 49

BCWPE-003 - Drug Profile 50

BLI-1008 - Drug Profile 51

BNC-375 - Drug Profile 52

CB-8411 - Drug Profile 54

centanafadine SR - Drug Profile 55

CM-4612 - Drug Profile 58

CTX-1301 - Drug Profile 59

CTX-1302 - Drug Profile 60

dasotraline hydrochloride - Drug Profile 61

dextroamphetamine - Drug Profile 64

dextroamphetamine IR - Drug Profile 65

dextroamphetamine MR - Drug Profile 66

edivoxetine hydrochloride - Drug Profile 68

eltoprazine - Drug Profile 70

fasoracetam - Drug Profile 75

guanfacine hydrochloride ER - Drug Profile 77

histamine dihydrochloride - Drug Profile 79

HTL-1071 - Drug Profile 80

INV-107 - Drug Profile 82

IRL-752 - Drug Profile 83

KP-415 CR - Drug Profile 84

levofacetoperane - Drug Profile 86

lisdexamfetamine dimesylate - Drug Profile 87

mazindol - Drug Profile 94

methylphenidate hydrochloride ER - Drug Profile 96

methylphenidate hydrochloride MR - Drug Profile 97

methylphenidate hydrochloride SR - Drug Profile 102

methylphenidate hydrochloride XR - Drug Profile 104

modafinil - Drug Profile 107

molindone hydrochloride ER - Drug Profile 108

niacinamide CR - Drug Profile 110

NLS-4 - Drug Profile 111

NLS-8 - Drug Profile 112

NT-0201 - Drug Profile 113

P-001 - Drug Profile 114

PBF-509 - Drug Profile 115

PD-2005 - Drug Profile 116

PD-3044 - Drug Profile 117

PFR-08001 - Drug Profile 118

PFR-8026 - Drug Profile 119

RP-5063 - Drug Profile 120

SHP-465 - Drug Profile 123

SKL-ADHD - Drug Profile 125

Small Molecule to Block Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 126

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder - Drug Profile 127

Small Molecules to Agonize NMDA2D for Attention Deficit Hyperactivity Disorder - Drug Profile 128

Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile 129

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile 130

Small Molecules to Inhibit Sodium Hydrogen Exchanger for ADHD - Drug Profile 131

Synthetic Peptide to Antagonize D2 for ADHD - Drug Profile 132

TS-141 - Drug Profile 133

Vaccine for CNS Disorders - Drug Profile 134

viloxazine hydrochloride ER - Drug Profile 135

vortioxetine hydrobromide - Drug Profile 137

VU-0238429 - Drug Profile 143

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects 144

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products 149

Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones 150

Featured News & Press Releases 150

Appendix 162

Methodology 162

Coverage 162

Secondary Research 162

Primary Research 162

Expert Panel Validation 162

Contact Us 162

Disclaimer 163

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Aevi Genomic Medicine Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Alcobra Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by APeT Holding BV, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arbor Pharmaceuticals LLC, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BioHealthonomics Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BioLite Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Curemark LLC, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DURECT Corp, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Eli Lilly and Company, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Ensysce Biosciences Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by H. Lundbeck A/S, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Heptares Therapeutics Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Highland Therapeutics Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Integrative Research Laboratories Sweden AB, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by INVENT Pharmaceuticals Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by KemPharm Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Luc Therapeutics Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Merck & Co Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Neos Therapeutics Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NeuroDerm Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Neurovance Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by NLS Pharma Group, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Noven Pharmaceuticals Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by P2D Bioscience, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Reviva Pharmaceuticals Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shire Plc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Sunovion Pharmaceuticals Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Supernus Pharmaceuticals Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Taisho Pharmaceutical Co Ltd, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by TRImaran Pharma Inc, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2017 (Contd..1), H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2017 (Contd..2), H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H1 2017 (Contd..3), H1 2017

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports